NCT01133210

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation

Detailed description

The purpose of this study is to determine, in obese insulin resistant subjects, the effect of maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation

Conditions

• Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	Maraviroc	dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
OTHER	placebo	subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-08-01
• Completion: 2012-11-01
• First posted: 2010-05-28
• Last updated: 2013-12-10

Locations

1 site across 1 country: United States